Studies have shown that elevated VEGF—especially in patients with residual disease—correlates with worse outcomes and is positively linked with malondialdehyde, suggesting a connection between angiogenesis and oxidative stress, making VEGF a key prognostic biomarker in ovarian cancer [66]. This evidence concerns the gene VEGFA and ovarian carcinoma.